...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** BETonMACE Trial is Fully Enrolled and Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: While we are waiting ...

Given that we will have numbers on secondary indications at Bio Europe I'll go with CAD $63 on the TSX on 15 Sept 2019, assuming that's a trading day.


New Message
Please login to post a reply